


Start-ups redefining the industry

30 May 2012 | News | By BioSpectrum Bureau

Trailblazers



Life sciences industry in the Asia Pacific recorded the double digit growth of 16.6 percent, reaching \$128.26 billion in 2010. Of this, pharma made up the major chunk of the revenue with 92 percent segment share, followed by MedTech with 6.6 percent share and the rest was filled up by biotech.

Many new biotech and pharma companies in Asia Pacific are making their mark in the industry with innovative R&D ideas. Start-up companies make significant contributions to the healthcare industry with their different way of thinking and by adopting innovation. 20 years ago, entrepreneurs had to seek start-up options in the West. But now with the help of angel investors, venture capitalists and government funding, starting a life sciences business in Asia Pacific is just as viable as doing so in the West. Consistent growth in APAC and financial crunches in the west has forced entrepreneurs to start a company in the APAC.

BioSpectrum has taken an initiative to identify these young start-up companies that have successfully taken the less trodden path and worked on major worldwide concerns and delivered results. Featured this week: Osprey Medical

Featured Companies

LanzaTech	Elastagen	Osprey Medical	
Biomics Biotechnologies	Endoluminal Sciences	Achira Labs	CellSievo

Sea6 Energy	Veristem Technologies	Shanghai BravoBio	<u>A</u> wak Technologies
HistoIndex	Mitra Biotech	APSN	BioValence
Wuhan Healthgen	LegoChem Biosciences	Clearbridge BioMedics	Verva Pharmaceuticals